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Aims: This analysis evaluated HbA1c-adjusted hypoglycemia risk with glargine versus neutral protamine
Hagedorn (NPH) over a 5-year study in patients with Type 2 diabetes mellitus (T2DM). Clinical signiﬁcance
was assessed using number needed to harm (NNH) to demonstrate the risk of one additional patient
experiencing at least one hypoglycemic event.
Methods: Individual patient-level data for symptomatic documented hypoglycemia and HbA1c values from a
5-year randomized study comparing once-daily glargine (n = 513) with twice-daily NPH (n = 504) were
analyzed. Symptomatic hypoglycemia was categorized according to concurrent self-monitoring blood glucose
levels and need for assistance. Hypoglycemic events per patient-year as a function of HbA1c were ﬁtted by
negative binomial regression using treatment and HbA1c at endpoint as independent variables. An estimate of
NNH was derived from logistic regression models.
Results: The cumulative number of symptomatic hypoglycemia events was consistently lower with glargine
compared with NPH over 5 years. Compared with twice-daily NPH, once-daily glargine treatment resulted in
signiﬁcantly lower adjusted odds ratios (OR) for all daytime hypoglycemia (OR 0.74; p = 0.030) and any
severe event (OR 0.64; p = 0.035), representing a 26% and 36% reduction in the odds of daytime and severe
hypoglycemia, respectively. Our model predicts that, if 25 patients were treated with NPH instead of glargine,
then one additional patient would experience at least one severe hypoglycemic event.
Conclusions: This analysis of long-term insulin treatment conﬁrms ﬁndings from short-term studies and
demonstrates that glargine provides sustained, clinically meaningful reductions in risk of hypoglycemia
compared with NPH in patients with T2DM.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
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Hypoglycemia is an important barrier to treatment for many
patients with Type 2 diabetes mellitus (T2DM) — in particular, those
with an extended duration of disease who receive insulin therapy
(Cryer, 2007; Frier, 2008). Fear of hypoglycemia is one of the key
factors that prevent good glycemic control because patients and
healthcare providers are discouraged from starting or intensifying
insulin treatment (Cryer, 1999, 2002; Korytkowski, 2002).
Short-term clinical trials have shown that use of long-acting
insulin analogues, such as glargine and insulin detemir, is associated
with fewer hypoglycemic events compared with conventional neutral
protamine Hagedorn (NPH) insulin therapy (Fritsche, Schweitzer, &
Haring, 2003; Massi-Benedetti, Humburg, Dressler, & Ziemen, 2003;
Riddle, Rosenstock, & Gerich, 2003; Rosenstock et al., 2001; Yki-
Jarvinen, Dressler, & Ziemen, 2000). A meta-analysis of 12 trials
comparing glargine with NPH conﬁrmed the beneﬁt of this analogue
in reducing the risk of hypoglycemia (Bazzano et al., 2008). A meta-
regression analysis that modeled the interaction between hypogly-
cemia and glycosylated hemoglobin (HbA1c) showed that glargine
was also associated with less risk of hypoglycemia than NPH, at any
given level of glycemic control (Mullins, Sharplin, Yki-Jarvinen,
Riddle, & Haring, 2007).
To date, the advantage of long-acting analogues has not been
conﬁrmed in long-term controlled studies under conditions similar to
clinical practice. The completion of a 5-year randomized study
comparing the effects of glargine versus NPH as basal insulin on
progression of retinopathy in patientswith T2DM(Rosenstock, Fonseca,
McGill, et al., 2009a) provided an opportunity to examine this issue in a
long-term setting, as has been done previously for other issues of
interest (Rosenstock, Fonseca, McGill, et al., 2009b). The original
analysis of the study showed a lower risk of hypoglycemiawith glargine
compared with NPH, without any differences in the rate of progression
of diabetic retinopathy (Rosenstock, Fonseca, McGill, et al., 2009a).
Our present analysis focused on several clinically relevant aspects
of hypoglycemia, including: 1) the cumulative time-course of
hypoglycemic events; 2) the relationship between hypoglycemic
events and HbA1c at endpoint; 3) rates of several categories of
hypoglycemia adjusted for HbA1c at endpoint and; 4) an endpoint
HbA1c-adjusted computation of the number needed to harm (NNH) for
one additional patient to experience at least one hypoglycemic event if
NPH is used rather than glargine. NNH is an important metric when
comparing medicines, as it directly examines a clinically relevant
treatment outcome over a set period of time. NNH compares the
outcomes for patients if they were treated with one therapy versus
their outcomes if they were treated with an alternative therapy. This
enables physicians to make treatment decisions based on evidence of
the potential harm of choosing one treatment over another.
2. Research design and methods
The analysis included hypoglycemia and HbA1c data from the 5-
year study, which compared randomized treatment with glargine
(once daily) or NPH (twice daily), both associated with oral
antidiabetic drugs (OADs), in order to assess retinopathy progression
(NCT00174824) (Rosenstock, Fonseca, McGill, et al., 2009a). Entry
criteria included: T2DM for at least 1 year; age 30–70 years old; HbA1c
6% − 12% at screening; stable OAD and/or insulin treatment; no prior
treatment with glargine or other analogues; and no proliferative or
severe non-proliferative diabetic retinopathy. Following randomiza-
tion, patients received open-label glargine once daily (usually at
bedtime) or NPH twice daily (usually in the morning and at bedtime).
Insulin doses were titrated over the ﬁrst 3 years of the study in both
groups, to achieve standard glycemic control as determined by fasting
plasma glucose (FPG) levels of ≤6.7 mmol/L (≤120 mg/dL). This
target was reduced to ≤5.5 mmol/L (≤100 mg/dL) for the ﬁnal2 years of the study but no systematic titration regimenwas enforced.
Intensiﬁcation of conventional therapy was allowed; therefore, in
addition to patients receiving basal insulin plus OADs, prandial insulin
(regular human insulin but not fast-acting analogues) could be added
with meals, at the investigator’s discretion, even if not used at
baseline. No speciﬁc titration guidelines were provided for prepran-
dial regular insulin dosing. Self-monitoring of blood glucose (SMBG)
was to be performed daily in the fasting state before breakfast using
an Accu-Chek blood glucose meter (Roche Diagnostics, Indianapolis,
IN, USA). All episodes of symptomatic hypoglycemia and all SMBG
values were recorded in patient diaries and reviewed by the site
personnel at each visit.
The original primary study outcome was the percentage of
patients with ≥3-step progression in Early Treatment Diabetic
Retinopathy Study (ETDRS) score after 5 years of treatment. Second-
ary study outcomes included various assessments of the progression
and severity of diabetic retinopathy, as published previously (Rosen-
stock, Fonseca, McGill, et al., 2009a). Additional secondary study
outcomes included HbA1c and FPG change from baseline, incidence
and rate of hypoglycemia, and insulin dose.
For the present report, further analyses were performed focusing
on HbA1c-adjusted hypoglycemia. Using individual patient-level data
from the source trial, the between-treatment comparison of the
proportion of patients with at least one hypoglycemic event adjusted
for HbA1c values achieved at study end was evaluated. Hypoglycemia
was grouped into six non-exclusive categories: (1) all symptomatic
hypoglycemia, conﬁrmed or not; (2) symptomatic hypoglycemia
conﬁrmed by SMBG b3.9 mmol/L (b70 mg/dL); (3) symptomatic
hypoglycemia conﬁrmed by SMBG b2.0 mmol/L (b36 mg/dL); (4)
severe hypoglycemia, deﬁned as symptomatic hypoglycemia requiring
third-party assistance and either with SMBG levels of ≤3.1 mmol/L
(≤56 mg/dL) or prompt recovery after oral carbohydrate, intravenous
glucose or glucagon administration; (5) all symptomatic daytime
hypoglycemia; (6) all symptomatic nocturnal hypoglycemia. Asymp-
tomatic, non-severe episodes were not included in this analysis.2.1. Analytical methods for hypoglycemia
The cumulative incidence of symptomatic hypoglycemic events
during the study (i.e. comparison of the two types of insulin) was
analysed graphically, without formal statistical testing. All hypogly-
cemic events were included in the analyses; this is different from the
previously reported analysis of hypoglycemia in this study (Rosen-
stock, Fonseca, McGill, et al., 2009a), in which events occurring in the
active titration period (ﬁrst 3 months) were not included owing to
the potential for increased rates of hypoglycemia associated with the
change in treatment, which may not be representative of long-term
therapy with the basal insulin. The treatment effects of glargine
compared with NPH, calculated from the logistic regressions, are
expressed as odds ratios (ORs) and the corresponding 95% conﬁdence
intervals (CIs), with two-sided p values under H0: OR = 1 adjusted
for HbA1c achieved at endpoint. Rates of the different categories of
hypoglycemia were also adjusted for HbA1c achieved at endpoint.
Hypoglycemic events per patient-year were plotted against HbA1c
achieved at endpoint and ﬁtted by negative binomial regression using
treatment and HbA1c achieved at endpoint as independent variables.
Number needed to harm was deﬁned as the number of patients to
be treated with NPH instead of glargine for one additional patient to
experience at least one hypoglycemic event. Number needed to harm
was calculated as NNH = 1/(pNPH−pglargine), where pNPH and pglargine
are the risks of one ormore hypoglycemia episodes adjusted for HbA1c
at endpoint in a person receiving NPH or glargine, respectively, under
the conditions of this study. These risks were derived from the
respective logistic regression model and are, therefore, adjusted for
endpoint HbA1c.
Table 2






Final insulin dose, U/day (SD)
Basal 62.1 (39.8) 73.0 (47.9) 0.0001
Prandiala 47.1 (42.4) 32.9 (35.6) b0.0001
Total 89.3 (66.5) 93.2 (66.9) 0.3646
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In the original trial, 1017 participants were randomized and
received treatment. The treatment groups formed by randomization
were generally well balanced in terms of baseline characteristics
(Table 1). A total of 498 and 486 patients in the glargine and NPH
groups, respectively, had complete information regarding HbA1c and
occurrence of hypoglycemia, and were included in this analysis.Final insulin dose, U/kg/day (SD)
Basal 0.623 (0.377) 0.738 (0.465) b0.0001
Prandiala 0.483 (0.424) 0.333 (0.372) b0.0001
Total 0.902 (0.660) 0.942 (0.672) 0.3495
Mean HbA1c, % (SD)
Baseline 8.4 (1.4) 8.3 (1.4) –
Endpoint 7.8 (1.3) 7.6 (1.3) –
Adjusted HbA1c change, % (SE)b −0.5 (0.1) −0.7 (0.1) Δ = −0.19
p = 0.012
Intention-to-treat population, patients who have HbA1c values at both baseline and
endpoint and data for occurrence of hypoglycemia. HbA1c = glycosylated hemoglobin;
NPH = neutral protamine Hagedorn; U = unit; SD = standard deviation; SE =
standard error.
a Sample size was 283 patients in the glargine group and 295 in the NPH group.
b Least squares mean HbA1c calculated using analysis of variance with actual
treatment group and pooled center as independent variables.3.1. Insulin dosage and glycemic control
Table 2 shows insulin dosages in the two groups at the end of the
study. Themean (±standard deviation [SD]) daily doses of once-daily
glargine were lower than those of twice-daily NPH, 62.1 ± 39.8 and
73.0 ± 47.9 U, respectively (Table 2). However, of the 283 and 295
patients in the glargine and NPH groups, respectively, requiring
prandial insulin (Table 2), the mean daily prandial doses at the end of
treatment were greater in the glargine group (mean ± SD: 47.1 ±
42.4 U and 32.9 ± 35.6 U; respectively). The total daily doses of
insulin were not signiﬁcantly different between the treatment groups.
At the end of the study, 43.2% of patients in the glargine group and
39.3% in the NPH group were taking basal insulin with OADs but
without prandial insulin.
Titration of basal insulin in both treatment groups was based on
FPG targets. Mean ± SD FPG levels decreased from baseline and were
similar at study end with glargine (10.5 ± 3.7 to 7.7 ± 3.2 mmol/L
[190 ± 66 to 140 ± 58 mg/dL]) and NPH (10.0 ± 3.4 to 7.7 ±
3.2 mmol/L [180 ± 61 to 139 ± 58 mg/dL]). As reported previously,
mean HbA1c levels decreased from baseline and remained stable to
the end of the study in both insulin treatment groups. The last on-
treatment values (mean ± SD) were 7.8% ± 1.3% with glargine and
7.6% ± 1.3% with NPH. The adjusted change (mean ± standard error
of the mean) from baseline was −0.5% ± 0.1% with glargine and
−0.7% ± 0.1% with NPH, p = 0.012).
The signiﬁcant difference between groups in the doses of basal and
prandial insulins, respectively, at the end of the study, raises the
question of whether there may be a subgroup effect of differing
treatment with prandial insulin. Investigation of this possible effect
found that there is a signiﬁcant difference between those who
received no prandial insulin and those who did receive prandial
insulin, for all hypoglycemia rates except for severe hypoglycemia.
The treatment effect, however, was homogeneous across the two
types of insulin except in the case of evening hypoglycemia, where the
treatment effect seemed to be strongly signiﬁcant for the group with
no prandial insulin, whereas the treatment effect for the group that
received prandial insulin showed no signiﬁcant effect. In the context
of this being a post-hoc analysis, and the consistent lack of interaction
effects for all other hypoglycemia parameters, this result can probably
be discounted.Table 1
Patient baseline characteristics (intention-to-treat population).
Glargine (n = 513) NPH (n = 504)
Age (years), mean ± SD 54.9 ± 8.8 55.3 ± 8.5
Age b65 years, n (%) 429 (83.6) 427 (84.7)
Female, n (%) 235 (45.8) 234 (46.4)
Weight (kg), mean ± SD 100.2 ± 22.7 98.7 ± 22.3
Height (cm), mean ± SD 170.1 ± 10.1 170.1 ± 10.3
Body mass index, kg/m2, mean ± SD 34.5 ± 7.2 34.1 ± 7.2
Duration of diabetes (years), mean ± SD 10.7 ± 6.9 10.8 ± 6.7
Prior use of OAD, n (%) 494 (96.3) 476 (94.4)
Prior use of insulin, n (%) 344 (67.1) 354 (70.2)
HbA1c at baseline (%), mean ± SD 8.4 ± 1.4 8.3 ± 1.4
NPH = neutral protamine Hagedorn; SD = standard deviation; OAD = oral
antidiabetic drug; HbA1c = glycosylated hemoglobin.3.2. Unadjusted incidence and event rates for
symptomatic hypoglycemia
The total number of symptomatic hypoglycemic events during the
5-year study period was higher with NPH, compared with glargine
(15,527 vs 11,995). The cumulative number of symptomatic hypo-
glycemia events was consistently higher with NPH compared with
glargine at all time points (Fig. 1). After approximately 2 years of
treatment, the rates (slopes) of cumulative symptomatic hypoglyce-
mic events were constant in both the NPH and insulin glargine
groups; before this time point, the curves of cumulative events were
steeper in both groups. Throughout the study period, rates of
symptomatic hypoglycemia were generally higher in the NPH insulin
group than in the insulin glargine group. Of note, the glargine arm had
less hypoglycemia despite the fact that during the study it had more
subjects on sulfonylureas (20.3% and 15.7% in the glargine and NPH
groups; respectively). Unadjusted rates of any symptomatic hypogly-
cemia event per patient-year were lower with glargine than with NPH
(5.3 vs 7.4 events/patient-year; p b 0.001).
3.3. HbA1c-adjusted incidence and event rates for categories
of hypoglycemia
Table 3 displays incidences and rates for various categories of
hypoglycemia without and with adjustment for HbA1c values attained
at the end of treatment. In all categories, the adjusted risk of
hypoglycemia was lower with glargine treatment than with NPH,
with adjusted ORs ranging from 0.64 to 0.86. The difference in risk of
experiencing one or more events was statistically signiﬁcant for all
symptomatic events conﬁrmed by SMBG, severe events, and all
daytime events. The rates of hypoglycemia expressed as events/
patient-year were also lower for all categories with glargine compared
with NPH (adjusted rate ratio [RR] ranging from 0.39 to 0.75). The
reduction of the event-rate with glargine compared with NPH was
statistically signiﬁcant for all categories except severe hypoglycemia.
Hypoglycemia incidence and event rates were also computed with
adjustment for individual patients’ HbA1c change from baseline to
endpoint (data not shown). Results of this sensitivity analysis showed
a pattern similar to the analysis with adjustment for HbA1c at
endpoint. Adjusted odds and rates were signiﬁcantly lower for
glargine compared with NPH for all categories of hypoglycemia,
with the exception of the odds of experiencing any symptomatic
event and the rate of severe hypoglycemic events.
Fig. 1. Cumulative number of symptomatic hypoglycemic events.
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of hypoglycemia
Regression curves showing the relationships between the rates of
hypoglycemia (events/patient-year) and HbA1c achieved at endpoint
for the two treatment groups are shown in Fig. 2. Rates were lower
with glargine than NPH at all levels of HbA1c. In these regression
analyses, the coefﬁcient for endpoint HbA1c was not signiﬁcantly
different from zero, suggesting that endpoint HbA1c had no signiﬁcant
inﬂuence on event rates.
3.5. Number needed to harm
Results of HbA1c-adjusted NNH analyses are shown in Table 4 and
Fig. 3. The number of patients to be treated with NPH instead of
glargine for one additional patient to experience at least one
symptomatic hypoglycemic event was 22; although, the difference
in incidences between the agents was not signiﬁcantly different from
zero (p = 0.068; Table 4 and Fig. 3). For events conﬁrmed by SMBGTable 3







Incidence of people experiencing at least one hypoglycemia event and odds ratios
Total (all symptomatic) 389 (78.1%) 405 (83.3%) 0
Symptomatic b2.0 mmol/L (b36 mg/dL) 153 (30.7%) 183 (37.7%) 0
Symptomatic b3.9 mmol/L (b70 mg/dL) 358 (71.9%) 380 (78.2%) 0
Severe 40 (8.0%) 60 (12.3%) 0
All daytime 326 (65.5%) 354 (72.8%) 0
All nocturnal 269 (54.0%) 282 (58.0%) 0
Rates of hypoglycemia per patient-yearb
U
(
Total (all symptomatic)c 5.346 (0.389) 7.449 (0.547) 0
Symptomatic b2.0 mmol/L (b36 mg/dL) 0.312 (0.039) 0.793 (0.095) 0
Symptomatic b3.9 mmol/L (b70 mg/dL) 4.845 (0.384) 6.785 (0.543) 0
Severec 0.041 (0.008) 0.065 (0.012) 0
All daytimec 3.843 (0.290) 5.426 (0.413) 0
All nocturnalc 1.514 (0.141) 2.017 (0.189) 0
Intention-to-treat population. HbA1c = glycosylated hemoglobin; NPH = neutral protamin
a Two-sided p value for the null hypothesis: odds ratio = 1 or rate ratio = 1, respective
b Hypoglycemia rates per patient-year from negative binomial regression.
c Standard error shown in parentheses.b3.9 mmol/L (b70 mg/dL), those conﬁrmed by SMBG b2.0 mmol/L
(b36 mg/dL), and severe events, the NNHs were 19, 16 and 25,
respectively, and all were statistically signiﬁcant.
4. Discussion
The analyses reported here extend our prior observation, outlined
in brief previously (Rosenstock, Fonseca, McGill, et al., 2009a), that
less hypoglycemia accompanied systematic treatment with glargine
than with NPH as basal therapy. These analyses differ from the earlier
analyses in several ways. Firstly, in the original report, hypoglycemic
events occurring in the ﬁrst 3 months of treatment were omitted to
minimize any possible effect of more active, early, insulin titration
with one regimen than the other (Rosenstock, Fonseca, McGill, et al.,
2009a). The present analysis included all events recorded throughout
the entire 5-year treatment period. Secondly, in the earlier analysis,
hypoglycemia was classiﬁed as all symptomatic, symptomatic
nocturnal, or severe. Here, we have divided hypoglycemic events
into additional categories, notably including two categories ofnadjusted odds ratio
95% CI)
p valuea Odds ratio (95% CI) adjusted
for HbA1c at endpoint
p valuea
.71 (0.52, 0.98) 0.039 0.74 (0.54, 1.02) 0.070
.73 (0.56, 0.96) 0.022 0.76 (0.58, 0.99) 0.038
.71 (0.53, 0.95) 0.023 0.74 (0.55, 1.00) 0.048
.62 (0.41, 0.95) 0.026 0.64 (0.42, 0.97) 0.035
.71 (0.54, 0.93) 0.012 0.74 (0.56, 0.97) 0.030
.85 (0.66, 1.09) 0.206 0.86 (0.67, 1.11) 0.259
nadjusted rate ratio
95% CI)
p valuea Rate ratio (95% CI) adjusted
for HbA1c at endpoint
p valuea
.71 (0.58, 0.87) b0.001 0.72 (0.59, 0.88) 0.001
.40 (0.29, 0.56) b0.001 0.39 (0.28, 0.55) b0.001
.70 (0.56, 0.87) 0.002 0.71 (0.57, 0.89) 0.003
.63 (0.38, 1.07) 0.087 0.63 (0.37, 1.07) 0.085
.69 (0.56, 0.86) b0.001 0.71 (0.57, 0.88) 0.001
.75 (0.58, 0.97) 0.028 0.75 (0.58, 0.97) 0.030
e Hagedorn; CI = conﬁdence interval.
ly.
Fig. 2.Hypoglycemic events per person-year. (A) All symptomatic events; (B) all daytime events; (C) all nocturnal events. In all three regression analyses, the coefﬁcient for endpoint
HbA1c was not signiﬁcantly different from zero. HbA1c = glycosylated hemoglobin; NPH = neutral protamne Hagedorn.
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relationship between HbA1c levels attained during treatment and the
risk of hypoglycemia. This approach was taken because of prior
observations that the rate of hypoglycemia in a given clinical situation
may be inﬂuenced by the intensity of clinical management, and thus
the average level of blood glucose and HbA1c achieved during
treatment. Without this adjustment, differences in the rate ofhypoglycemic events between therapies may be obscured by
differences in the clinical efﬁcacy of treatments. Finally, to better
describe the potential clinical signiﬁcance of these ﬁndings, an
estimate of the NNH was derived from the HbA1c-adjusted incidences
of different categories of hypoglycemia. The NNH for one additional
patient to experience at least one clinical event is the reciprocal of the
absolute risk increase by NPH compared to glargine, and is a
Table 4
Analysis of HbA1c-adjusted number needed to harm with NPH vs Glargine.
NPH–Glargine 486/498
NNH (95% CI) p valuea
Total hypoglycemia (all symptomatic)b 22 [−∞, − 293)∪(11,+∞]c 0.0682
Symptomatic b2.0 mmol/L
(b36 mg/dL)
16 (9, 279) 0.0377
Symptomatic b3.9 mmol/L
(b70 mg/dL)
19 (10, 1213) 0.0466
Severed 25 (13, 326) 0.0340
All daytime 16 (9, 152) 0.0291
All nocturnal 28 [−∞, −37)∪(11,+∞]c 0.2583
Increased hypoglycemia with NPH indicated by 1 ≤ NNH b ∞; NNH = number needed
to harm; CI = conﬁdence interval; SMBG = self-monitoring of blood glucose.
a Two-sided p-value for the null hypothesis NNH = ± ∞.
b Irrespective of time of day and SMBG values.
c ∪ indicates the set union of the disjoint intervals.
d Symptomatic hypoglycemia requiring assistance and having either SMBG
≤3.1 mmol/L or prompt recovery after oral carbohydrate, intravenous glucose, or
glucagon administration.
747J. Rosenstock et al. / Journal of Diabetes and Its Complications 28 (2014) 742–749commonly used method of describing the ﬁndings of controlled trials
in a more clinically relevant way (Cook & Sackett, 1995; Tramer &
Walder, 2005; Walter, 2001).
Using these methods, the present analyses conﬁrm the implications
of the earlier, simpler, analysis. Although total daily insulin doses were
similar with glargine and NPH, there were approximately 29% fewer
hypoglycemic events reported with glargine compared with NPH
treatment. However, the reduction in HbA1c from baseline was slightly
greater with NPH than with glargine treatment, resulting in approxi-
mately 0.2% lower mean HbA1c at endpoint. Consequently, it could be
argued that the greater frequency of hypoglycemia with NPH may be
related to the slightly lower HbA1c, and thus mean daily glucose levels.Fig. 3.HbA1c-adjusted number needed to harm analysis. *Deﬁned as symptomatic hypoglyce
oral carbohydrate, intravenous glucose, or glucagon administration; HbA1c = glycosylated
SMBG = self-monitoring of blood glucose; CI = conﬁdence interval.When hypoglycemia incidences and event rates were adjusted for
individually attained HbA1c levels, most of the categories of
hypoglycemia studied still showed signiﬁcantly lower risk of
hypoglycemia with glargine than with NPH. Notably, for events
conﬁrmed by SMBG b3.9 and b2.0 mmol/L, the odds ratios for
hypoglycemia were 0.74 and 0.76 (odds lower with glargine by 26%
and 24%), respectively, with glargine versus NPH (p b 0.05 for both).
For severe hypoglycemia, an odds ratio of 0.64 – i.e. 36% lower odds of
an event with glargine versus NPH – was observed (p = 0.035).
Analysis of event rates, which included multiple events in individuals,
also showed signiﬁcant differences. Risk reduction with glargine
versus NPH was 29% (rate ratio = 0.71) for events conﬁrmed by
SMBG b3.9 mmol/L (p = 0.003) and 61% (rate ratio = 0.39) for
events conﬁrmed by SMBG b2.0 mmol/L (p b 0.001). Taken together,
these data demonstrate that adjustment for HbA1c levels during the
study support the conclusion that hypoglycemia was less frequent
and problematic with glargine compared with NPH. An exploratory
subgroup analysis found that the reduced risk for hypoglycemia was
consistent in both people receiving regular human insulin, as well as
basal insulin and in people only receiving basal insulin.
Converting HbA1c-adjusted data into NNH values demonstrated the
potential clinical relevance of these ﬁndings. The NNH with NPH rather
thanglargine inorder for oneadditional patient to experience at least one
event of hypoglycemia (all six categories) over 5 years ranged from16 to
28 patients treated with NPH (depending on the level and timing of
hypoglycemia), all in a range that might assist with clinical decision-
making.Mostnotably, theanalysis demonstrated that, if 25patientswere
treated with NPH rather than glargine over 5 years, then one additional
patient would experience at least one episode of severe hypoglycemia.
Strengths of these analyses include prospectively planned hypo-
glycemia data collection over the course of 5 years in a randomized
study, and the consistency in results across the different categories ofmia requiring assistance and having either SMBG≤3.1 mmol/L or prompt recovery after
hemoglobin; NPH = neutral protamine Hagedorn; NNH = number needed to harm;
748 J. Rosenstock et al. / Journal of Diabetes and Its Complications 28 (2014) 742–749hypoglycemia (symptomatic, daytime, nocturnal). Persistence of the
differences in frequency of hypoglycemia between the treatment
groups after adjustment for HbA1c achieved at endpoint strengths the
conclusion that a glargine-based regimen is indeed associated with
less hypoglycemia.
One limitation of this study is the difference in dosing frequency
between the groups. Glargine was dosed once daily at bedtime and
NPH twice daily, at bedtime and in the morning. The difference in the
risk of hypoglycemia observed between groups could conceivably be a
result of this dosing frequency. The mean daily basal insulin dose at
endpoint was lower with glargine versus NPH but the prandial dose
requirement was greater; as such, there was no signiﬁcant difference
in themean total daily insulin dose between treatment groups at study
endpoint. Ameta-analysis comparing once-daily glargine versus once-
daily NPH showed that glargine was associated with a signiﬁcant
relative reduction in the risk of symptomatic hypoglycemia, suggest-
ing that dosing frequency does not explain the observed differences in
the present study (Home, Fritsche, Schinzel, &Massi-Benedetti, 2010).
The present study represents a robust analysis of the risk of
hypoglycemia with basal insulin given the extended duration of the
study, which is longer than any previous trials. Previous meta-analyses
of short-term clinical trials are also consistent in showing a lower risk of
hypoglycemia with the long-acting insulin analogues, glargine and
insulin detemir, compared with traditional intermediate-acting insu-
lins, such as NPH (Horvath, Jeitler, Berghold, et al., 2007; Monami,
Marchionni, &Mannucci, 2008),with implications for bothquality of life
andmedical outcomes. In addition, hypoglycemia has a negative impact
on the resources of healthcare systems (Heaton, Martin, & Brelje, 2003;
Leese, Wang, Broomhall, et al., 2003; Lundkvist, Berne, Bolinder, &
Jonsson, 2005; Rhoads et al., 2005), with signiﬁcant additional costs
associated with hypoglycemic events. Several studies across the world
have demonstrated the high costs of hypoglycemia (Ali, White, Lee, et
al., 2008; Allicar et al., 2000; Amiel, Dixon, Mann, & Jameson, 2008;
Bullano, Fisher, Grochulski, Menditto, & Willey, 2006; Grima, Thomp-
son, & Sauriol, 2007; Jonsson, Bolinder, & Lundkvist, 2006; Lee, Balu,
Cobden, Joshi, & Pashos, 2006; Palmer, Lammert, & Hermansen, 2008;
Reviriego et al., 2008). Implementation of therapy with long-acting
insulin analogues, such as glargine, has been shown to decrease the rate
of hypoglycemic events, as well as the costs associated with their
occurrence (Bullano, Al-Zakwani, Fisher, Menditto, & Willey, 2005;
Bullano et al., 2006; Leichter, 2008; McEwan, Poole, Tetlow, Holmes, &
Currie, 2007; Rhoads et al., 2005; Zhang & Menditto, 2005). Moderate-
to-severe hypoglycemia, in particular, is associated with signiﬁcant
expenditure on a per-patient basis and was estimated to incur costs in
excess of US$ 3000 per year, or a mean cost per event of US$ 1087
(Bullano et al., 2005; Rhoads et al., 2005). Given the lowNNHwith NPH
in the present analysis, further studies might examine whether this
translates into lower treatment costs for glargine relative toNPH,which
has a much higher risk of hypoglycemia, during long-term therapy.
In summary, this analysis of hypoglycemia in a large, long-term
study contributes to the growing body of evidence and adds
translational perspective that, compared with NPH, glargine provides
a clinically meaningful reduction in the risk of hypoglycemia in
patients with T2DM.
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